NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy.

[1]  A. Takeshita,et al.  Probucol Attenuates Left Ventricular Dysfunction and Remodeling in Tachycardia-Induced Heart Failure: Roles of Oxidative Stress and Inflammation , 2002, Circulation.

[2]  M. Hori,et al.  The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. , 2002, Journal of the American College of Cardiology.

[3]  A. Shah,et al.  Pivotal Role of a gp91phox-Containing NADPH Oxidase in Angiotensin II-Induced Cardiac Hypertrophy in Mice , 2002, Circulation.

[4]  K. Node,et al.  Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. , 2001, The Journal of clinical investigation.

[5]  W. Aird,et al.  Vascular endothelial growth factor induces manganese‐superoxide dismutase expression in endothelial cells by a Racl‐regulated NADPH oxidase‐dependent mechanism , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  C. Kramer,et al.  Combined Angiotensin II Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition Further Attenuates Postinfarction Left Ventricular Remodeling , 2001, Circulation.

[7]  U. Laufs,et al.  Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. , 2001, Molecular pharmacology.

[8]  Koichi Tanaka,et al.  Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. , 2001, Journal of the American College of Cardiology.

[9]  K. Jan,et al.  NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. , 2000, Circulation research.

[10]  J. Shapiro,et al.  Intracellular Reactive Oxygen Species Mediate the Linkage of Na+/K+-ATPase to Hypertrophy and Its Marker Genes in Cardiac Myocytes* , 1999, The Journal of Biological Chemistry.

[11]  M. D. Richard A. Walsh,et al.  Journal of Molecular and Cellular Cardiology: Changing of the Guard , 1999 .

[12]  E. Neer,et al.  Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Takeshita,et al.  Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. , 1998, Circulation research.

[14]  W R Taylor,et al.  Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. , 1998, Hypertension.

[15]  K. Mihara,et al.  Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. , 1998, Circulation.

[16]  H. Matsubara,et al.  Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. , 1998, Circulation.

[17]  K. Chien,et al.  Rho Is Required for Gαq and α1-Adrenergic Receptor Signaling in Cardiomyocytes , 1996, The Journal of Biological Chemistry.

[18]  R. Vasan,et al.  The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. , 1996, Archives of internal medicine.

[19]  V. Ferrans,et al.  Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. , 1996, The Biochemical journal.

[20]  Shokei Kim,et al.  Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. , 1995, Hypertension.

[21]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[22]  H. Matsubara,et al.  Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. , 1993, Circulation research.

[23]  D. Harrison,et al.  Hypercholesterolemia increases endothelial superoxide anion production. , 1993, The Journal of clinical investigation.

[24]  M. Ruzicka,et al.  The Renin‐Angiotensin System and Volume Overload‐Induced Cardiac Hypertrophy in Rats Effects of Angiotensin Converting Enzyme Inhibitor Versus Angiotensin II Receptor Blocker , 1993, Circulation.

[25]  S. Powers,et al.  HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. , 1993, The Journal of biological chemistry.

[26]  S. Chien,et al.  Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  N. Kaplan.  Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. , 1988, The New England journal of medicine.

[28]  E. Frohlich.  Cardiac hypertrophy in hypertension. , 1987, The New England journal of medicine.

[29]  T. Matsubara,et al.  Increased superoxide anion release from human endothelial cells in response to cytokines. , 1986, Journal of immunology.

[30]  G. Dorn,et al.  Gq signaling in cardiac adaptation and maladaptation. , 1999, Trends in cardiovascular medicine.

[31]  K. Chien,et al.  Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. , 1996, The Journal of biological chemistry.